Intellectual, dynamic atmospheres that attract outstanding researchers interested in solving complex problems of biomedicine
Independent organizations closely affiliated with USC and the Keck School, institutes are defined both by a physical space and research vision and provide a place for in-depth, integrative studies.
- Cardiovascular and Thoracic Institute
- Clinical and Translational Sciences Institute
- Diabetes and Obesity Research Institute
- Eli and Edythe Broad Center for Stem Cell Research and Regenerative Medicine
- Emerging Pathogens and Human Immunology
- Genetic Medicine
- Global Health
- Health Promotion and Disease Prevention
- Institute for Urology
- Norris Comprehensive Cancer Center
- Translational Genomics
- USC Alzheimer’s Therapeutic Research Institute
- USC Gayle and Edward Roski Eye Institute
- USC Institute for Biomedical Therapeutics
- USC Mary and Mary Stevens Institute for Neuroimaging and Informatics
- Zilkha Neurogenetic Institute
Our institutes bring world-leading researchers together in a collaborative environment to provide solutions to problems in human health. Our institutes serve as a hub for multidisciplinary collaboration and innovation in research.
The USC Alzheimer’s Therapeutic Research Institute (USC ATRI), located in San Diego, CA, is a world leader in the clinical development and testing of novel treatments for Alzheimer’s disease through innovative, collaborative, multicenter clinical trials. ATRI’s collaboration with Keck investigators, including Drs. Arthur Toga and Paul Thompson at the USC Mark and Mary Stevens Neuroimaging and Informatics Institute, Dr. Helena Chui at the Alzheimer’s Disease Research Center, and Dr. Berislav Zlokovic at the Zilkha Neurogenetic Institute, facilitates rapid progress in data sharing and analytical methods central to the drug development process. USC ATRI the Keck School’s main outlet for clinical testing of new treatments for Alzheimer’s Disease.
Director: Paul Aisen, MD
Our investigators are exploring the normal mechanisms that build, maintain and repair our body systems to develop knowledge-based approaches for regenerative medicine. Scientists are researching kidney, liver, neural, blood, cardiovascular, skeletal and skin disease models. The center serves as a hub for USC Stem Cell, which connects researchers in stem cell biology and regenerative medicine across USC.
Director: Andy McMahon, PhD
During the past decades, the global public health community has been challenged by the emergence and rapid worldwide spread of threatening pathogens. As the Keck School of Medicine locates in the heart of Los Angeles metropolitan, the USC Institute for Emerging Pathogens and Immune Diseases serves as an umbrella structure and the intellectual and operational home for a world-class infectious diseases and immunology research programs. The institute provides the leadership and key collaborative expertise needed for assembly of interdisciplinary teams focused on large-scale research projects directed toward the problem of world-threatening pathogens, including HIV, cancer-causing virus, Zika/Dengue/Chikungunya virus, avian flu, and tuberculosis. The institute also develops and supports educational and training programs for USC student, postdocs, and faculty, as well as outreach to the local community.
Director: Jae Jung
This center brings together more than 60 researchers to conduct interdisciplinary basic, translational, clinical, community and population research into the causes, prevention and treatment of obesity, diabetes and their complications. The Center offers pilot funding and core facilities to support biochemical assays and human studies.
The USC Mark and Mary Stevens Neuroimaging and Informatics Institute (INI) aims to enhance discovery through the application of imaging and information technologies in the study of the brain. The Institute is dedicated to excellence in data acquisition, analysis, stewardship and computational innovation for the purpose of biomedical research.
Working at the interface of medicine and engineering, the Institute of Biomedical Therapeutics’ (IBT) vision is to transform bioengineered neural interfaces into treatments for patients for whom there is no foreseeable cure. Using an interdisciplinary approach, our mission is to further the basic understanding of debilitating neural conditions, ultimately leading to the development of novel diagnostic and treatment options. IBT’s researchers and clinicians represent a diverse group of individuals who bring cross-disciplinary expertise in several areas, including chemistry, bioengineering, neuroscience, electronics, pharmacology, imaging, materials science and business. Unique in-house facilities include biomedical engineering labs, a clean room, machine shop and electronics facilities, creating dynamic and collaborative working environment that fosters innovation and discover.
Director of IBT, Mark Humayun, MD, PhD, received the nation’s highest award for achievement in technology in May 2016 for his development of the Argus II, the only FDA-approved retinal prosthesis system that allows those with certain blinding diseases to regain some useful vision.
Director: Mark Humayun, MD, PhD
Established in 2010, the Southern California Clinical and Translational Science Institute (SC CTSI) is one of 60 NIH-funded Clinical Translational Science Awards with a mandate to increase the efficiency and quality of translational research. SC CTSI helps accelerate scientific discoveries and their application in real-life settings in order to address the specific health needs of urban and diverse populations and improve human health by helping researchers obtain the education, resources and collaborations necessary to translate discoveries into practice.
USC Norris Comprehensive Cancer Center scientists work toward a complete understanding of the most fundamental aspects of cancer. They study the abnormal cell growth characteristic of cancer to determine what goes wrong and how the process can be altered. They then work to quickly translate those findings into treatment and prevention strategies. The National Cancer Institute (NCI) has designated the USC Norris Comprehensive Cancer Center as one of the nation’s 45 comprehensive cancer centers, a select group of institutions providing leadership in cancer treatment, research, prevention and education.
Director: Stephen Gruber, MD, PhD, MPH
The Zilkha Neurogenetic Institute (ZNI), established in 2003, is an integral part of a broader USC neuroscience initiative promoting collaboration between researchers from diverse disciplines. The Zilkha Neurogenetic Institute was designed to foster interactions among the best and brightest. Scientists at the institute reach across boundaries to embrace methods and techniques from other fields of study, identifying new approaches to examine nervous system function so we may all better understand the underlying causes of neurological and psychiatric disorders.
Director: Berislav Zlokovic, PhD
Research at CHLA focuses on pediatric diseases and treatments and is ranked as one of the top pediatric research programs in the nation. The Saban Research Institute manages and leads all research endeavors.